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Sir,
In countries in which PSA-based screening has been widely
adopted, prostate cancer has a high incidence-to-mortality ratio
(e.g., 6.5 in the United States) (Jemal et al, 2008), and after
prostatectomy, up to 50% of screen-detected cancers are
pathologically characterised as indolent (Steyerberg et al, 2007;
Jemal et al, 2008). Surgery and radiotherapy have an excellent
track record of cancer control but are accompanied by risks of
urinary and sexual morbidity (Sanda et al, 2008). For these
reasons, we are enthusiastic about efforts to identify men who are
most likely to benefit from treatment, as well as novel paradigms
aimed at reducing treatment-related morbidity without compro-
mising effectiveness (Eggener et al, 2007, 2009). The article by
Ahmed et al (2009) describes a commendable effort to investigate
the oncological and functional outcomes after whole-gland high-
intensity-focused ultrasound (HIFU) for localised prostate cancer.
Most patients who elect treatment of their prostate cancer expect
to achieve all three components of an ideal outcome: long-term
durable cure of their cancer, maintenance or improvement of
urinary function, and preservation of erectile function. The data
presented by Ahmed et al raise concerns about the ability of HIFU
to satisfactorily and reliably achieve these goals.
First, interpretation of cancer recurrence data is complicated by
inadequate patient follow-up, conflicting information, and over-
stated conclusions. Recurrence after HIFU was defined as a PSA
nadir 40.5ngml
1 or a nadir o0.5ngml
1 and two consecutive
rises. However, the mean follow-up in the cohort was slightly less
than 1 year. As PSA measurements were obtained every 3 months
and roughly a third of the patients were given hormonal therapy to
reduce gland size before HIFU, it is likely that most men have not
been followed up long enough to meet the criteria for recurrence.
Reporting discrepancies were also identified that warrant further
clarification. In the Results section, the authors state that the
lowest PSA achieved by a patient was 0.12ngml
1; in contrast,
Table 3 states that 35–40% had a PSA o0.05ngml
1. In addition,
12 months after treatment, the mean PSA is reported to be
0.65ngml
1, the maximum PSA 1.02ngml
1, and 58% of patients
had a PSA o0.2ngml
1. According to our calculations, it is
impossible for all three of these statements to occur simulta-
neously. The authors state that cancer control after HIFU is
equivalent to radical prostatectomy, as 60% of patients had a PSA
o0.2ngml
1 2 years after treatment. This exuberant claim of
equivalence seems to be premature and unfounded, as 88 and 72%
of patients after prostatectomy have a PSA o0.2ngml
1 at 5
(Nielsen et al, 2008) and 10 (Stephenson et al, 2006) years,
respectively, after treatment. Finally, as inclusion criteria mandate
an estimated prostate volume of less than 40cm
3, approximately
half of the patients are excluded or require androgen deprivation
therapy (Pettus et al, 2009), which is associated with a significant
number of side effects.
Second, after treatment, 24% of patients were treated for a
urinary tract infection and 32% required an intervention for
urinary debris or urethral stricture. Given the relatively high rate
of strictures, longer-term data are required to assess the impact of
HIFU on urinary function.
Third, the investigators performed analyses on the basis of two
separate definitions of potency: an erection hard enough for
penetration ‘much less than half the time’ or ‘about half the time’.
Presumptively, for most men with reliable erections before
treatment, attaining a satisfactory erection on 50% or fewer
attempts would be disappointing and would be considered as a
major adverse impact of treatment. In addition, the authors
erroneously state in the Conclusions section that two-thirds of the
patients had erections sufficient for intercourse. However, this is
based on 12 patients meeting the pre-treatment criteria of
erections hard enough ‘about half the time’, with 8 maintaining
that loose definition after treatment.
Registry trials of HIFU are ongoing and we anticipate longer-
term outcome data. On the basis of the early data from this report,
we are sceptical whether HIFU is capable of adequately providing
the oncological and functional outcomes that patients and
physicians are striving to achieve.
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